Objective To explore the differences in gut microbiota among different histopathologi-cal subtypes of lung cancer.Methods A total of 80 lung cancer patients admitted to the Department of Oncology and Hematology of Anqing First People's Hospital from February 2020 to February 2024 were selected as study subjects.Meanwhile,80 healthy volunteers who underwent physical examina-tions during the same period were selected as control group.According to pathological examination re-sults,the lung cancer patients were divided into three subgroups:lung squamous cell carcinoma group,lung adenocarcinoma group,and lung small-cell cancer group.The 16S ribosomal RNA(16S rRNA)sequencing technology was used to compare the differences in gut microbiota diversity and the characteristics of species relative abundance between lung cancer patients with different patho-logical grades and the control group.Results The proportion of patients with a family history of lung cancer was higher in different lung cancer subtypes than in the control group,and the difference was statistically significant(P＜0.05).The abundance-based coverage estimator(ACE)index,Simpson index,and Shannon index of patients with different lung cancer pathological subtypes were all lower than those in the control group,and the differences were statistically significant(P＜0.05).β-diver-sity analysis showed that there were significant differences in the variation of gut microbial community structure between the control group and lung cancer patients with different pathological types(P＜0.05).The results of LEfSe indicated that there were differences in gut characteristic microbiota among patients with different pathological subtypes.Specifically,Megamonas was enriched in the LUAD group,Butyrivibrio was enriched in the LSCC group,and Akkermansia was enriched in the SCLC group.Conclusion There are significant differences in the composition of gut microbiota between lung cancer patients and the normal population,and the gut microbiota of patients with different lung cancer pathological subtypes have distinct characteristics.These differences may provide new bio-markers and therapeutic strategies for the diagnosis and treatment of lung cancer.

Objective To investigate the efficacy and safety of hypofractionated thoracic radiotherapy combined with EP chemotherapy in the treatment of limited-stage small-cell lung cancer (LS-SCLC). Methods A total of 117 patients with LS-SCLC were enrolled and randomly divided into test group (n=59) and control group (n=58). Patients in the experiment group were given hypofractionated thoracic radiotherapy combined with EP chemotherapy, while patients in the control group were given hyperfractionation radiotherapy combined with EP chemotherapy. Objective response rate (ORR), 2-year overall survival (OS), 2-year progression free survival (PFS), and immune cell level were used to evaluate clinical efficacy. We compared the incidence of side effects between the two groups. Results After the treatment, the ORR of patients in the test group was higher than that in the control group (P > 0.05). The mean OS and PFS of patients in the test group were significantly longer than those in the control group (P < 0.05). The levels of CD3⁺, CD4⁺, CD4⁺/CD8⁺, and NK cells in the test group were significantly higher, whereas the levels of CD8⁺ were significantly lower than those in the control group (P < 0.05). The incidence of radiation pneumonitis, radiation esophagitis, and severe dermatitis in the test group was significantly lower than that in the control group (P < 0.05). Conclusion Hypofractionated radiotherapy combined with EP chemotherapy for treatment of LS-SCLC can effectively improve the anticancer efficacy and patient survival, reduce the damage to the body's immune function, and alleviate adverse reaction of radiotherapy.

Metabolic syndrome has become a major health issue in patients with schizophrenia. Antipsychotic medications can induce metabolic disturbances and the features of these metabolic disturbances vary across different drugs and populations. Metabolic side effects of antipsychotic drugs have been duplicated in animal models, in which the translational validity can be influenced by experimental designs. The energy imbalance and change of appetite-regulating hormones may play important roles in antipsychotic-induced metabolic disturbances. This review introduces antipsychotic-induced weight gain and glucose dysregulation and then demonstrates the research progress on animal models and regulating mechanisms of appetite and feeding behaviors and the related problems remained to be explored.

Metabolic syndrome has become a major health issue in patients with schizophrenia. Antipsychotic medications can induce metabolic disturbances and the features of these metabolic disturbances vary across different drugs and populations. Metabolic side effects of antipsychotic drugs have been duplicated in animal models, in which the translational validity can be influenced by experimental designs. The energy imbalance and change of appetite-regulating hormones may play important roles in antipsychotic-induced metabolic disturbances. This review introduces antipsychotic-induced weight gain and glucose dysregulation and then demonstrates the research progress on animal models and regulating mechanisms of appetite and feeding behaviors and the related problems remained to be explored.